Vivani Medical In Deal With Novo Nordisk To Evaluate Semaglutide Drug Implant NPM-139
BRUSSELS (dpa-AFX) - On Tuesday, Vivani Medical, Inc. (VANI), a biopharmaceutical company focused on ultra long-acting drug implants, announced a new agreement, under which Novo Nordisk B A/S (NVO) will evaluate its semaglutide drug implant NPM-139 for chronic weight management.NPM-139, a miniature…